$262 Million is the total value of Artia Global Partners LP's 25 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVO | New | NOVO-NORDISK A Sadr | $50,218,584 | – | 371,055 | +100.0% | 19.14% | – |
| LLY | New | LILLY ELI & CO | $38,167,356 | – | 104,328 | +100.0% | 14.55% | – |
| ARGX | New | ARGENX SEsponsored adr | $32,277,831 | – | 85,204 | +100.0% | 12.30% | – |
| MRK | New | MERCK & CO INC | $29,312,990 | – | 264,200 | +100.0% | 11.17% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $19,505,966 | – | 99,267 | +100.0% | 7.43% | – |
| ABBV | New | ABBVIE INC | $14,677,582 | – | 90,821 | +100.0% | 5.59% | – |
| MRNA | New | MODERNA INC | $13,421,027 | – | 74,719 | +100.0% | 5.12% | – |
| ISEE | New | IVERIC BIO INC | $10,803,807 | – | 504,615 | +100.0% | 4.12% | – |
| BIIB | New | BIOGEN INC | $8,307,600 | – | 30,000 | +100.0% | 3.17% | – |
| SGEN | New | SEAGEN INC | $6,576,499 | – | 51,175 | +100.0% | 2.51% | – |
| BNTX | New | BIONTECH SEsponsored ads | $5,574,364 | – | 37,108 | +100.0% | 2.12% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $5,374,800 | – | 45,000 | +100.0% | 2.05% | – |
| AZN | New | ASTRAZENECA PLCsponsored adr | $5,272,060 | – | 77,759 | +100.0% | 2.01% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $3,795,508 | – | 15,971 | +100.0% | 1.45% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $2,920,177 | – | 28,217 | +100.0% | 1.11% | – |
| TMO | New | THERMO FISHER SCIENTIFIC INC | $2,801,911 | – | 5,088 | +100.0% | 1.07% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $2,455,310 | – | 22,321 | +100.0% | 0.94% | – |
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $2,201,472 | – | 41,600 | +100.0% | 0.84% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $2,054,381 | – | 7,114 | +100.0% | 0.78% | – |
| New | MODERNA INCcall | $1,796,200 | – | 10,000 | +100.0% | 0.68% | – | |
| VKTX | New | VIKING THERAPEUTICS INC | $1,230,582 | – | 130,913 | +100.0% | 0.47% | – |
| VRNA | New | VERONA PHARMA PLCsponsored ads | $1,043,920 | – | 39,951 | +100.0% | 0.40% | – |
| WAT | New | WATERS CORP | $974,640 | – | 2,845 | +100.0% | 0.37% | – |
| New | AMYLYX PHARMACEUTICALS INC | $882,477 | – | 23,883 | +100.0% | 0.34% | – | |
| KYMR | New | KYMERA THERAPEUTICS INC | $748,800 | – | 30,000 | +100.0% | 0.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NOVO-NORDISK A S | 4 | Q3 2023 | 25.8% |
| MERCK & CO INC | 4 | Q3 2023 | 14.1% |
| ARGENX SE | 4 | Q3 2023 | 12.3% |
| LILLY ELI & CO | 4 | Q3 2023 | 14.5% |
| ABBVIE INC | 4 | Q3 2023 | 5.6% |
| ASTRAZENECA PLC | 4 | Q3 2023 | 5.4% |
| SEAGEN INC | 4 | Q3 2023 | 4.5% |
| BIOMARIN PHARMACEUTICAL INC | 4 | Q3 2023 | 4.3% |
| NEUROCRINE BIOSCIENCES INC | 4 | Q3 2023 | 2.1% |
| VERTEX PHARMACEUTICALS INC | 4 | Q3 2023 | 2.6% |
View Artia Global Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
View Artia Global Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.